Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion Baseline
Description Intervention
Criteria/ Population Measures Outcomes
Systems (1) met with participants abnormal baseline ABC-C
subscale, 12
BioMarin (1) during each scheduled laboratory test results inappropriate weeks, mean
Boehringer- evaluation. The treating • History of adverse speech subscale, change ± SD:
Ingelheim (1) clinician reviewed efficacy events or failed mean ± SD: G1: -3.4 ± 6.1
Bristol-Myers ratings, monitored and treatment while taking G1: 5.3 ± 3.7 G2: -2.9 ± 5.0
Squibb (5) recorded adverse events. two or more SSRIs G2: 5.0 ± 3.7 G1/G2: P = NS
Eli Lilly (4)
Forest Labs (3)
The evaluating clinician
was blinded to adverse
• Prior treatment with
citalopram or
Repetitive
behavior:
Communication/
language:
Impax (1) events and monitored escitalopram oxalate CYBOCS-PDD, ABC-C inappro-
IntegraGen (1) efficacy using CGI-I, • Recent initiation of mean ± SD:
Janssen (4) CYBOCS-PDD, RBS-R, behavior therapy G1: 15.1 ± 1.8
Johnson & ABC-C questionnaires. • History of bipolar G2: 15.0 ± 2.1
Johnson (3) Groups:
disorder or manic RBS-R subscale,
McNeil (1) G1: citalopram
episode
mean ± SD:
Nastech (2) G2: placebo
• Concomitant treatment Compulsive
Neuropharm (5) Co-interventions held with psychotropic G1: 7.0 ± 5.4
Novartis (1) stable during treatment: medications or G2: 5.9 ± 4.3
Otsuka (1) NR
medication having Restrictive:
Pfizer (1) Frequency of contact known interactions with G1: 4.7 ± 2.8
Sanofi-Aventis (2) during study:
citalopram
G2: 4.1 ± 3.0
Seaside
Baseline and at week 12 Age, years ± SD (range): Ritualistic:
Therapeutics (2) Concomitant therapies, G1: 9.1 ± 3.2 (5.0-17.3) G1: 7.0 ± 4.8
Shire Pharma (2) n:
G2: 9.6 ± 3.1 (5.1-17.1) G2: 6.9 ± 4.5
Supernus (1) Sleep medication: NR Mental age:
Sameness:
UCB Pharma (2) N at enrollment: Non-verbal IQ > 70, n (%): G1: 11.2 ± 7.4
Wyeth (2) G1: 73
G1: 43 (61.4)
G2: 10.2 ± 6.9
Design: G2: 76
G2: 43 (60.6)
Self-injurious:
RCT
N at follow-up:
Gender, n (%):
G1: 2.8 ± 3.0
G1: 60
Male:
G2: 2.6 ± 2.6
G2: 63
G1: 64 (87.7)
G2: 64 (84.2)
priate speech
subscale, 12
weeks, mean
change ± SD:
G1: -0.8 ± 2.9
G2: -0.8 ± 2.5
G1/G2: P = NS
Repetitive
behavior:
CYBOCS-PDD,
12 weeks, mean
change ± SD:
G1: -2.0 ± 3.4
G2: -1.9 ± 2.5
G1/G2: P = NS
RBS-R subscale,
12 weeks, mean
change ± SD:
Compulsive:
G1: -1.8 ± 3.9
G2: -1.3 ± 3.2
G1/G2: P = NS
King et al.,
Race/ethnicity, n (%): Stereotyped: Restrictive:
2009 (continued)
Hispanic:
G1: 6.8 ± 4.0 G1: -0.6 ± 2.6
G1: 9 (12.5)
G2: 6.1 ± 3.9 G2: -0.9 ± 2.5
G2: 8 (10.5)
ABC-C stereotypy G1/G2: P = NS
American Indian or subscale, mean ± Ritualistic:
Alaskan native:
SD:
G1: -1.6 ± 3.5
G1: 0
G1: 7.2 ± 4.8 G2: -1.5 ± 3.4
G2: 2 (2.6)
G2: 7.2 ± 4.5 G1/G2: P = NS
Asian:
Commonly Sameness:
G1: 6 (8.2)
occurring co- G1: -3.0 ± 6.0
G2: 8 (10.5)
morbidities: G2: -2.4 ± 5.3
Black:
ABC-C irritability G1/G2: P = NS
G1: 7 (9.6)
subscale, mean ± Self-injurious:
G2: 10 (13.2)
SD:
G1: -0.4 ± 3.0
Native Hawaiian: G1: 13.2 ± 8.8 G2: -0.7 ± 2.0
G1: 1 (1.4)
G2: 11.2 ± 8.5 G1/G2: P = NS
G2: 0
ABC-C hyper- Stereotyped:
White:
activity subscale, G1: -1.2 ± 3.2
G1: 53 (72.6)
mean ± SD: G2: -1.1 ± 2.7
G2: 55 (72.4)
G1: 20.2 ± 11.7 G1/G2: P = NS
Other:
G2: 20.2 ± 11.2 ABC-C stereo-
G1: 6 (8.2)
typy subscale, 12
G2: 4 (5.3)
weeks, mean
SES:
change ± SD:
Maternal education: NR
G1: -0.7 ± 4.5
Household income: NR
G2: -1.0 ± 3.3
C-62